Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab plus Chemotherapy in Recurrent or Advanced Endometrial Cancer
NCT06066216Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Feb 2024
- Primary completion
- Oct 2025
- Modality
- Bispecific Antibodies
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in endometrial cancer (EC), sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Objective Response Rate at 2 years. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
cadonilimab
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT06066216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06066216.